Personalised Cancer Medicine in the Clinic Personalised Medicine: Ethical, economic and implementation barriers A framework for personalized approaches to ovarian cancer The Tumor Microenvironment Drives Intra-tumoral Heterogeneity in Chemotherapeutic Response TESTING HIGH RISK CHILDHOOD CANCER PATIENT CELLS IN VITRO FOR POTENTIAL NEW DRUG TREATMENTS Targeting transcription factors in cancer – a hard road, but more likely to reach the destination? Effect of combining EGFR-targeted therapy and metabolic inhibitors in the treatment of sarcoma Do patients with advanced cancer want to discuss and pay for unfunded expensive anticancer drugs? Functional genomics of BRAF-driven glycolysis in BRAF^V600 melanoma EPIGENETICS INFORMING FUTURE TREATMENT STRATEGIES FOR HIGH GRADE SEROUS OVARIAN CANCER – LOOKING TO HISTONES, UBIQUITIN AND CHROMATIN RELAXATION THE ACRF DRUG DISCOVERY CENTRE: AN EARLY-STAGE DRUG DISCOVERY SERVICE Modelling personalised medicine in high-risk neuroblastoma The role of centrosomal protein, TAX1BP2 in chemo-sensitivity of hepatocellular carcinoma cell  A role for the free beta subunit of human chorionic gonadotropin in sensitivity of high grade serous cancer cells to platinum-based chemotherapeutics A novel anti-cancer agent that sensitizes neuroblastoma cells to chemotherapy and targets cellular metabolism Harnessing the power of serum microRNAs to predict surgical outcome for women with ovarian cancer CBL0137, a novel NFkB suppressor and p53 activator, is highly effective in two independent pre-clinical mouse models of neuroblastoma New, highly selective MRP1 inhibitors show promising preclinical activity in neuroblastoma NOVEL THERAPEUTICS FOR MIXED LINEAGE LEUKAEMIA IN INFANTS Investigating the therapeutic potential of targeting ABCE1 in neuroblastoma New Approach to AML Therapy: Inhibition of rDNA Transcription by CX-5461 Assessing an in vitro model of cultured patient-derived xenografts for predicting treatment response in vivo Development and characterisation of Aurora A kinase inhibitor MLN8237 resistant leukaemia cells TP53 mutation and p53 immunohistochemistry in high grade serous ovarian cancer. The Bright Alliance - new ways of working